Rigel Pharmaceuticals
RIGL
163 hedge funds and large institutions have $500M invested in Rigel Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 56 increasing their positions, 44 reducing their positions, and 14 closing their positions.
36% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 14
27% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 44
15% more call options, than puts
Call options by funds: $3.32M | Put options by funds: $2.89M
3% more funds holding
Funds holding: 159 → 163 (+4)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.27% less ownership
Funds ownership: 8.32% → 8.05% (-0.27%)
19% less capital invested
Capital invested by funds: $615M → $500M (-$115M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
+$6.95M |
| 2 |
LCM
Laurion Capital Management
New York
|
+$4.43M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$3.69M |
| 4 |
TA
Tamarack Advisers
Carlsbad,
California
|
+$2.36M |
| 5 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$2.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$22.2M |
| 2 |
State Street
Boston,
Massachusetts
|
-$7.85M |
| 3 |
Wells Fargo
San Francisco,
California
|
-$4.4M |
| 4 |
Millennium Management
New York
|
-$2.28M |
| 5 |
Citigroup
New York
|
-$1.67M |
RIGL Hedge Fund Activity: Q3 2021 in Review
163 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q3 2021, worth a combined $500M — down 19% from $615M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new RIGL positions and 14 closed out — a net gain of 5 holders — while 56 added to existing stakes and 44 trimmed.
The largest buyer was HealthInvest Partners, opening a new position worth an estimated $6.95M. The largest seller was Wellington Management Group, cutting an estimated $22.2M.
- 163 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q3 2021, up from 159 in Q2 2021.
- Funds reported $500M of Rigel Pharmaceuticals stock for Q3 2021, down 19% quarter-over-quarter.
- 19 funds opened new Rigel Pharmaceuticals positions in Q3 2021 and 14 closed out, a net change of +5 holders.
- The largest Rigel Pharmaceuticals buyer in Q3 2021 was HealthInvest Partners, an estimated $6.95M added.
- The largest Rigel Pharmaceuticals seller in Q3 2021 was Wellington Management Group, an estimated $22.2M sold.
Based on aggregated 13F filings for Q3 2021.